While short-term administration has been effective in specific complications, such as SBP and HRD-AKI, long-term treatment may benefit patients with stable decompensated cirrhosis and grade 2 or 3 uncomplicated ascites, especially if it adequately increases serum albumin levels (see below). This evidence concerns the gene ALB and acute kidney injury.